Piper Jaffray analyst JP Kim kept his Overweight rating and $150 price target on DexCom, saying the company's acquisition of TypeZero Technologies is a "smart strategic decision". Kim notes the purchase is moving the company one step closer to "becoming a diabetes service company that provides the best in class Continuous Glucose Monitoring and also decision support to patients". The analyst adds that his latest meeting with the management suggest that both demand and penetration of CGM has "accelerated meaningfully" over the last several months and is also sustainable.